A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy

ConditionType 2 Diabetes Mellitus (T2DM)

Trial statusNot yet recruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age19+

SponsorAddpharma Inc.

About this trial

The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Signed informed consent

Other inclusions applied

Disqualifiers

Subjects with severe diabetic complications

Other exclusions applied

Trial design

Design model

Parallel

Treatments tested in this trial

AD-233A
Drug
PO, Once daily(QD), 24 weeks
AD-233B
Drug
PO, Once daily(QD), 24 weeks
AD-233C
Drug
PO, Once daily(QD), 24 weeks
AD-233D
Drug
PO, Once daily(QD), 24 weeks
AD-233A Placebo
Drug
PO, Once daily(QD), 24 weeks
AD-233B Placebo
Drug
PO, Once daily(QD), 24 weeks

Treatment groups

354 Participants

are divided into 3 treatment groups

Group A: Test GroupExperimental treatment 4 interventions

Group B: Control Group 1Active comparator 4 interventions

Group C: Control Group 2Active comparator 4 interventions

Trial outcomes

Primary outcomes

Change in HbA1c(Hemoglobin a1c) from baseline at Week 24 after administration of IP(Investigator's Product)

Time frame

Baseline, Week 24

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Addpharma Inc.

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: